AUS
NZ
UK
CA
USA
IND
Haleon plc (LSE/NYSE: HLN), the consumer health company known for brands such as Sensodyne, Panadol, and Centrum, has announced that its Chief Financial Officer, Dawn Allen, received a vesting of shares under the Haleon Performance Share Plan on 30 June 2026. This award, originally granted in October 2024, was contingent on performance conditions through 31 December 2025, with full details of targets and achievements available in the company's 2025 Annual Report and 20-F. A portion of the vested shares was automatically sold to cover Dawn Allen's tax obligations resulting from the vesting. This disclosure complies with the UK Market Abuse Regulation and constitutes an initial notification of a transaction by a Person Discharging Managerial Responsibilities.
Key Points
- Company: Haleon plc, ticker HLN, listed on London Stock Exchange and NYSE
- CFO Dawn Allen received vesting of a Haleon Performance Share Plan (Buyout Award) on 30 June 2026
- Total shares acquired at no cost: 283,193.151771 ordinary shares including accrued dividends
- 133,300.732432 shares were automatically sold at a33.523867 each to cover tax liabilities from the vesting
- The award is subject to malus, clawback provisions, and retention requirements for Executive Directors
- Investors should monitor additional PDMR transactions and Haleon's shareholder remuneration progress
Details and Background of the Performance Share Plan Award
The disclosed vesting relates to an award granted to Dawn Allen in October 2024 under the Haleon Performance Share Plan, structured as a Buyout Award. Vesting depended on continued employment through the vesting date and meeting performance conditions over the period ending 31 December 2025, as approved by Haleon's Remuneration Committee.
The vesting includes dividends accrued during the award’s life, so the total shares delivered reflect both the original performance-linked grant and reinvested dividends. Specific performance targets and achievement levels are detailed in the company’s 2025 Annual Report and 20-F, rather than this regulatory notification.
Share Acquisition Transaction on 30 June 2026
The shares were acquired on 30 June 2026 outside a recognised trading venue, typical for share plan vestings where shares transfer from a trust or nominee rather than being bought on the open market. Dawn Allen acquired 283,193.151771 Haleon ordinary shares (ISIN GB00BMX86B70) at nil cost, reflecting the nature of performance share plan awards.
The fractional share amount arises from the dividend accrual mechanism, which adds equivalent share value in lieu of cash dividends. This filing is an initial notification, confirming it as the first regulatory disclosure related to this vesting event.
Automatic Sale of Shares to Cover Tax at a33.523867 per Share
Simultaneously with vesting, 133,300.732432 shares were automatically sold on 30 June 2026 on the London Stock Exchange (XLON) at a33.523867 per share. This sale was arranged to satisfy income tax and National Insurance liabilities arising from the vesting, a standard UK practice for share awards.
The sale of approximately 47% of the vested shares aligns with HMRC withholding rules, based on the market value at vesting. Although the exact tax amount was not disclosed, investors can estimate gross proceeds from the price and volume. The net shares retained by Dawn Allen after this disposal represent her after-tax benefit, though the final holding was not specified in this notice.
Retention and Holding Requirements for Executive Directors
The shares acquired are subject to retention until Dawn Allen meets Haleon's CFO shareholding requirement, ensuring alignment with shareholder interests through sustained personal exposure to the company’s share price.
Additionally, Executive Directors, including the CFO, must hold these shares for at least two years post-vesting, complying with the UK Corporate Governance Code to discourage short-termism. This reflects Haleon's commitment to best practice executive remuneration.
Malus and Clawback Conditions on the Award
The vested award remains subject to malus and clawback provisions after vesting. Malus allows the Remuneration Committee to reduce or cancel unvested awards under certain conditions, while clawback permits recovery of value from vested awards in cases such as financial misstatement or misconduct.
These provisions mean the economic benefit to the CFO is not unconditional at vesting. Specific clawback periods and triggers are detailed in Haleon's remuneration policy in the 2025 Annual Report.
Compliance with UK Market Abuse Regulation and Disclosure
This announcement complies with the UK Market Abuse Regulation (UK MAR), requiring Persons Discharging Managerial Responsibilities to notify their employer and regulatory authorities within three business days of transactions. The vesting occurred on 30 June 2026, with notification published on 2 July 2026.
Haleon's Legal Entity Identifier (LEI) is 549300PSB3WWEODCUP19. The filing is an initial notification submitted by Amanda Mellor, Haleon's Company Secretary, consistent with standard UK practice. Haleon's dual listing on LSE and NYSE means it is also subject to US securities disclosure rules, possibly prompting parallel filings.
Dawn Allen's Role as Haleon CFO
Dawn Allen serves as Chief Financial Officer at Haleon plc, playing a key role in financial strategy, capital allocation, and investor relations. As an Executive Director, her shareholdings are governed by Remuneration Committee guidelines, and her share transactions are closely watched by investors as indicators of insider alignment.
The vesting of over 283,000 shares under a performance-based plan significantly increases her economic stake, despite the tax-related sale. Investors may interpret this equity accumulation as positive for long-term management and shareholder alignment. The immediate share price impact was not evident from public data.
Haleon's Consumer Health Business and Equity Award Context
Haleon operates independently following its 2022 demerger from GSK, with shares trading on the LSE and NYSE. Its portfolio covers six major categories: Oral Health, Vitamins, Minerals and Supplements, Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health, including brands like Sensodyne, Panadol, Advil, Centrum, Voltaren, Theraflu, Otrivin, parodontax, and Polident.
Serving over one billion consumers globally through healthcare professionals, Haleon's operational scale forms the backdrop for its executive performance targets. The performance conditions for this award, detailed in the 2025 Annual Report and 20-F, relate to the company's operational and financial results over the performance period. Investors seeking full details should consult those documents.
Investor Considerations on PDMR Activity
Notifications of this type provide transparency on executive equity remuneration and changes in beneficial ownership by senior management. Dawn Allen’s acquisition of over 283,000 shares through a performance-based plan, offset partly by tax-related sales, is a significant transaction for investors assessing management confidence and alignment.
Investors should monitor further disclosures from Haleon’s PDMRs as additional awards from the 2024 grant cycle vest. The retention requirements mean any future sale of retained shares will require separate UK MAR notification. For comprehensive details on performance targets and outcomes, investors should refer to the 2025 Annual Report and 20-F filings.
